Apomorphine intranasal - Nano PharmaSolutions
Alternative Names: Apomorphine nasal spray - Nano PharmaSolutions; NT-301Latest Information Update: 04 Jul 2025
At a glance
- Originator Nano PharmaSolutions
- Class Analgesics; Antiparkinsonians; Aporphines; Catechols; Erectile dysfunction therapies; Phenanthrenes; Piperidines; Quinolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 08 May 2025 Nano Pharmasolutions has patents pending for 'Therapeutic agent nanoparticles and methods of preparation' in USA
- 01 May 2025 Preclinical trials in Parkinson's disease in USA (Intranasal) prior to May 2025 (Nano PharmaSolutions pipeline, May 2025)
- 20 Apr 2025 Nano PharmaSolutions plans a phase I pharmacokinetic trial (In volunteers) in Australia (Intranasal, Powder) in April 2025 (NCT06954428)